2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 902

Inhibitor of DNA Binding 1 As a Fibroblast Derived Inflammatory Angiogenic Agonist in Rheumatoid Arthritis
Abstract Number: 3095

Initial Results of a Pilot Juvenile Localized Scleroderma (jLS) Comparative Effectiveness Study
Abstract Number: 1831

Initial Risk Factor Profile and Long-Term Cardiovascular Outcome in Women with Systemic Lupus Erythematosus
Abstract Number: 1502

Initiating Statin Medication and Risk of Fatigue in Rheumatoid Arthritis
Abstract Number: 2107

Initiation of Combination Triple Therapy in Real World Clinical Practice Rarely Replicates the Protocols Used in Randomized Controlled Trials.
Abstract Number: 1564

Initiation of Disease Modifying Therapies and Subsequent Weight Change in Rheumatoid Arthritis
Abstract Number: 1787

Innate Immunity, Arterial Inflammation and Vascular Stiffness in Patients with Systemic Lupus Erythematosus
Abstract Number: 201

Innate Lymphoid Cells Are Present at Normal Human Enthesis Providing a Potential Mechanism for Spondyloarthropathy Pathogenesis
Abstract Number: 1365

Innate Lymphoid Cells. New Players in Systemic Sclerosis Correlate with Extent of Skin and Lung Fibrosis
Abstract Number: 3097

Innovative Approach for the Identification of an Appropriate Dose Regimen of a Targeted Treatment, NI-0501, an Anti-Interferon Gamma (IFNg) Antibody, in Patients with Hemophagocytic Lymphohistiocytosis (HLH)
Abstract Number: 423

Institutional and Regional Variation in Childhood SLE 30-Day Hospital Readmission Rates: A Comparative Effectiveness Research Using the Pediatric Health Information System Database
Abstract Number: 2974

Insulin Resistance Is Associated with the Digital Ulcer in Patients with Systemic Sclerosis
Abstract Number: 1797

Insulin Resistance Is Not Associated with Increased Risk of Subclinical Atheromatosis in Patients with Systemic Lupus Erythematosus from Northern Spain
Abstract Number: 1128

Insulin-Induced Cartilage Degradation in Osteoarthritis Is Associated to Defective Autophagy
Abstract Number: 88

Integrating Evidence for Genetic Association and Natural Selection Helps Detect New Systemic Lupus Erythematosus Risk Loci in African-Americans

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].